Mr. Philippe Dubuc reports

THERATECHNOLOGIES TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

Theratechnologies Inc. will release financial results and provide a business update for its fourth quarter and full year ended Nov. 30, 2023, on Wednesday, Feb. 21, 2024, at 8:30 a.m. ET.

Theratechnologies will also provide further information on the complete response letter issued by the United States Food and Drug Administration in response to the company's supplemental biologics licence application for the F8 formulation of tesamorelin.

The call will be hosted by Paul Levesque, president and chief executive officer. Mr. Levesque will be joined by other members of the management team, including senior vice-president and chief financial officer Philippe Dubuc, senior vice-president and chief medical officer Dr. Christian Marsolais, and global commercial officer John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least 10 minutes in advance to secure access. Conference call dial-in and replay information can be found herein.

Conference call information

Conference call date:  Feb. 21, 2024

Conference call time:  8:30 a.m. ET

Dial-in numbers:  1-888-317-6003 (toll-free) or 1-412-317-6061 (international)

Access code:  0664356

Conference call replay

Toll-free:  1-877-344-7529 (United States) or 1-855-669-9658 (Canada)

International toll:  1-412-317-0088

Replay access code:  3842515

Replay end date:  Feb. 28, 2024

An archived webcast will also be available on the company's website.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.